GlassScriptPhysician profile
Jolanta Sledzik
NPI 1699476036
$2,695.65
in general payments reported to CMS, 2019-2025
17 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $65.55 · 2024: $917 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.64 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $345.45 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $325.81 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $319.79 | 2024-2025 | Voquezna |
| Amgen INC. | $172.95 | 2024-2025 | Repatha, Otezla, Repatha |
| Ardelyx, INC. | $166.36 | 2024-2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $161.25 | 2025 | Gemtesa |
| Pfizer INC. | $144.43 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $143.19 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.67 | 2023-2025 | Jardiance |
| Shield Therapeutics INC | $84.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $77.23 | 2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.95 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $48.67 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $24.29 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.94 | 2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $15.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolanta Sledzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.